The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...